Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCH | P24723 | 6/20 | 0.43 |
| ▸ | PRKCQ | Q04759 | 6/20 | 0.43 |
| ▸ | PRKCE | Q02156 | 5/20 | 0.43 |
| ▸ | PRKCD | Q05655 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.38 |
| ▸ | PKN1 | Q16512 | 2/20 | 0.38 |
| ▸ | PKN2 | Q16513 | 2/20 | 0.38 |
| ▸ | PRKCA | P17252 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | PRKCB | P05771 | 2/20 | 0.38 |
| ▸ | LATS1 | O95835 | 1/20 | 0.38 |
| ▸ | LATS2 | Q9NRM7 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3808178 | 0.79 | POLB (0.45) | PRKCHPRKCQPRKCEPRKCDALDH1A1 | |
| SCHEMBL27879846 | 0.77 | RAB9A (0.46) | ALDH1A1GAALMNASMN1; SMN2NPC1 | |
| SCHEMBL8131156 | 0.74 | PRKCH (0.43) | PRKCHPRKCEALDH1A1GAALMNA | |
| SCHEMBL3809777 | 0.73 | PRKCH (0.43) | PRKCHPRKCQPRKCEPRKCDGAA | |
| SCHEMBL7367384 | 0.73 | ALDH1A1 (0.44) | ALDH1A1GAALMNASMN1; SMN2NPC1 | |
| Hydrochloric Acid SCHEMBL28301442 | 0.72 | PRKCH (0.43) | PRKCHPRKCEALDH1A1GAALMNA | |
| SCHEMBL2296005 | 0.72 | ALDH1A1 (0.50) | PRKCHPRKCQPRKCEPRKCDALDH1A1 | |
| SCHEMBL10730331 | 0.71 | SYK (0.50) | — | |
| SCHEMBL6702643 | 0.71 | PRKCH (0.45) | PRKCHPRKCQPRKCEPRKCDROCK2 | |
| SCHEMBL3846786 | 0.70 | KDM4E (0.47) | ALDH1A1GAALMNASMN1; SMN2ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1296974-B1 | 2-CYANOPYRROLIDINE DERIVATIVES AND THEIR USE AS MEDICAMENTS | NOVARTIS AG (CH) | 2009-08-05 | — | — | EP | disclosed |
| EP-1296974-A2 | 2-CYANOPYRROLIDINE DERIVATIVES AND THEIR USE AS MEDICAMENTS | Novartis AG (CH) | 2003-04-02 | — | — | EP | disclosed |
| US-20020193390-A1 | Pharmaceutical compositions containing an N-(substituted glycyl)-2- cyanopyrrolidine and at least one other antidiabetic agent and their use in inhibiting dipeptidyl peptidase-IV | VILLHAUER EDWIN BERNARD (US) | 2002-12-19 | — | — | US | disclosed |
| US-6432969-B1 | NON-INSULIN DEPENDENT DIABETES, OBESITY, ARTHRITIS, AND OSTEOPOROSIS TREATMENT | NOVARTIS AG (CH) | 2002-08-13 | — | — | US | disclosed |
| WO-2001096295-A2 | 2-CYANOPYRROLIDINE DERIVATIVES AND THEIR USE AS MEDICAMENTS | NOVARTIS AG (CH) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193390-A1 | Pharmaceutical compositions containing an N-(substituted glycyl)-2- cyanopyrrolidine and at least one other antidiabetic agent and their use in inhibiting dipeptidyl peptidase-IV | DPP4, DPP9, DPP7 | PRKCH 1018/4885PRKCQ 1324/4885PRKCE 1046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.